MedTrace Logo

Pharmacokinetics of Two Eletriptan Oral Formulations Given With and Without Water and the Commercial Tablet Formulation Given With Water

NCT00871806 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2021-01-27

No results posted yet for this study

Summary

The study will evaluate whether the blood concentrations of eletriptan administered using two test formulations of oral disintegrating tablets are comparable to those observed with the standard commercial tablet.

Conditions

  • Healthy Volunteers

Interventions

DRUG

Commercial tablet with water

40 mg tablet, given once to each subject

DRUG

ODT #1 without water

40 mg tablet given once to each subject

DRUG

ODT #2 without water

40 mg tablet given once to each subject

DRUG

ODT #1 with water

40 mg tablet given once to each subject

DRUG

ODT #2 with water

40 mg tablet given once to each subject

Sponsors & Collaborators

  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2009-04-30
Completion
2009-04-30

Countries

  • Singapore

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00871806 on ClinicalTrials.gov